^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2024
Excerpt:
HR-Negative and HER2-Negative (Triple-Negative Breast Cancer...Germline BRCA1/2 mutation...PARPi (olaparib, talazoparib) (Category 1, preferred)
Source:
Published date:
12/10/2021
Excerpt:
Recommendation 1.4...Patients with metastatic triple-negative breast cancer with germline BRCA1 or 2 mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting may be offered an oral poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib or talazoparib) rather than chemotherapy...
DOI:
10.1200/JCO.21.01374
Source:
Title:
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Published date:
07/19/2018
Excerpt:
A PARPi (olaparib or talazaparib) is a reasonable treatment option for patients with BRCA-associated advanced TNBC or luminal (after progression on ET) ABC, previously treated with an anthracycline with/without a taxane (in the adjuvant and/or metastatic setting), since its use is associated with a PFS benefit, improvement in QoL and a favourable toxicity profile.
DOI:
10.1093/annonc/mdy192
Title:
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Source:
Title:
Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negative test Predicción de la sensibilidad a Olaparib en pacientes con cáncer de mama HER2 negativo localmente avanzado irresecable o metastásico con mutaciones en BRCA1, BRCA2, PALB2, RAD51C o RAD51D o con niveles bajos RAD51
Excerpt:
...Los pacientes deben ser hombres o mujeres de ≥18 años 3.Los pacientes deben de tener la capacidad de proporcionar un formulario de consentimiento informado por escrito firmado y fechado antes de cualquier procedimiento, muestreo y análisis.4.Cáncer de mama confirmado histológica o citológicamente con evidencia de enfermedad localmente avanzada5.Los pacientes pueden tener cáncer de mama triple negativo y HER2 negativo o cáncer de mama ER / PgR positivo, siempre que sean HER2 negativo y coherentes con los estándares locales y las pautas más recientes de ASCO CAP Cohorte 1: Mutación en BRCA1, BRCA2, PALB2, RAD51C o RAD51D 6.Pacientes que hayan recibido platino y no haya habido evidencia de progresión de la enfermedad durante la quimioterapia.7.Pacientes que hayan recibido platino y / o inhibidores de PARP y que hayan transcurrido al menos 6 meses entre la última dosis de PARP. ...
Trial ID:
Source:
Title:
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Excerpt:
...Assess the efficacy of olaparib in HER2-negative early Breast Cancer and HRD (BRCA 1/2 mutations and/or HRD positive). ...
Trial ID:
More C2 evidence
Source:
Title:
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
Excerpt:
...Cohort 1: Documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
Trial ID:
Source:
Title:
ANZ 1103 Study of Olaparib Clinical Effect in Patients with Breast Cancer or Ovarian Cancer
Excerpt:
...b) Male or female with histologically confirmed, metastatic breast cancer and documented BRCA1 or BRCA2 germline mutation, regardless of tumour steroid hormone receptor or HER-2 status OR...
Trial ID:
Source:
Title:
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
Excerpt:
...Mutation of BRCA 1 and/or 2 for ARM B only...
Trial ID:
Source:
Title:
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Excerpt:
...For patients enrolling in the sporadic serous epithelial ovarian cancer group, Group B, a negative family history (BRCAPRO score less than or equal to 20% or negative BRCA1/2 mutation test)....
Trial ID:
Source:
Title:
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Excerpt:
...- Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
Trial ID:
Source:
Title:
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Excerpt:
...Histologically confirmed recurrent and metastatic TNBC patients without BRCA1/2 mutation and BRCA1 promoter methylation....
Trial ID:
Less C2 evidence
Source:
Title:
Optimizing the management of early stage TNBC
Published date:
10/09/2021
Excerpt:
More recently, for patients with BRCA-mutated cancers, the OlympiA trial showed benefit to a year of adjuvant olaparib.
Trial ID:
Source:
Title:
184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer (ID 3933)
Published date:
09/28/2019
Excerpt:
Among five patients harboring pathogenic BRCA1/2 mutations (4 germline, 1 somatic) all responded to olaparib, and n = 3/5 obtained pathological complete response.
Trial ID:
Source:
Title:
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
Published date:
08/04/2023
Excerpt:
We here describe the case of a patient with BRCA1 mutated advanced BC and a long history of response to chemotherapy and immunotherapy who received systemic treatment with olaparib….Gene testing showed a germline BRCA1 deleterious variant...At disease progression, she was eligible for systemic third-line therapy with olaparib (300 mg twice daily) and had a complete response after 6 months of therapy and a PFS of 40 months at the time of writing.
Secondary therapy:
FEC
DOI:
https://doi.org/10.3389/fonc.2023.1214660
Source:
Title:
A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy
Published date:
12/01/2021
Excerpt:
We present the case of a 31-year-old woman with a chief complaint of a left breast mass....Left breast cancer(cT1cN0M0, cStage Ⅰ, triple negative type)was diagnosed...a BRCA1 mutation was identified on genetic testing....Thereafter, olaparib was started, and treatment was continued while maintaining partial response(PR).
Source:
Title:
17P - New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
Published date:
03/02/2023
Excerpt:
Combination of olaparib with Cx43-enriched vesicles distinctively enhanced olaparib efficacy against de novo resistant BRCA1 mutated TNBC cells versus the drug alone….These results, protected by a EU patent, reveal Cx43 as a dual promising novel therapeutic target to increase the efficacy and to resensitize de novo resistant BRCA1 mutated TNBC to PARPi olaparib
Secondary therapy:
Cx43 agonist
Source:
Title:
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model
Published date:
01/31/2021
Excerpt:
We further demonstrated that combined treatment of Brca1-mutant mammary tumors with irradiation and AZD2281, which inhibits PARP, significantly reduced tumor progression and extended survival.
DOI:
10.7150/ijbs.53667
Source:
Title:
Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer
Published date:
05/15/2020
Excerpt:
The MDA-MB-436 cell line with a splice site mutation in BCRA1 was less sensitive to both treatments, but there was modest synergy when the two drugs were combined.
DOI:
10.1158/1538-7445.AM2020-2212
